Gerald W. Mclaughlin - Net Worth and Insider Trading

Gerald W. Mclaughlin Net Worth

The estimated net worth of Gerald W. Mclaughlin is at least $28,175 dollars as of 2024-05-04. Gerald W. Mclaughlin is the CEO of Neos Therapeutics Inc and owns about 24,500 shares of Neos Therapeutics Inc (NEOS) stock worth over $28,175. Details can be seen in Gerald W. Mclaughlin's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Gerald W. Mclaughlin has not made any transactions after 2018-12-06 and currently still holds the listed stock(s).

Transaction Summary of Gerald W. Mclaughlin

Gerald W. Mclaughlin Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Gerald W. Mclaughlin owns 4 companies in total, including Neos Therapeutics Inc (NEOS) , Skye Bioscience Inc (SKYE) , and Aytu BioPharma Inc (AYTU) among others .

Click here to see the complete history of Gerald W. Mclaughlin’s form 4 insider trades.

Insider Ownership Summary of Gerald W. Mclaughlin

Ticker	Comapny	Transaction Date	Type of Owner
NEOS	Neos Therapeutics Inc	2020-03-13	director & Chief Executive Officer
SKYE	Skye Bioscience Inc	2014-10-31	director
AYTU	Aytu BioPharma Inc	2021-03-19	director
		2022-10-01	director

Gerald W. Mclaughlin Latest Holdings Summary

Gerald W. Mclaughlin currently owns a total of 1 stock. Gerald W. Mclaughlin owns 24,500 shares of Neos Therapeutics Inc (NEOS) as of December 6, 2018, with a value of $28,175.

Latest Holdings of Gerald W. Mclaughlin

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
NEOS	Neos Therapeutics Inc	2018-12-06	24,500	1.15	28,175

Holding Weightings of Gerald W. Mclaughlin

Gerald W. Mclaughlin Form 4 Trading Tracker

According to the SEC Form 4 filings, Gerald W. Mclaughlin has made a total of 0 transactions in Neos Therapeutics Inc (NEOS) over the past 5 years. The most-recent trade in Neos Therapeutics Inc is the acquisition of 17,097 shares on December 6, 2018, which cost Gerald W. Mclaughlin around $36,075.

Insider Trading History of Gerald W. Mclaughlin

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Gerald W. Mclaughlin Trading Performance

GuruFocus tracks the stock performance after each of Gerald W. Mclaughlin's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Gerald W. Mclaughlin is 5.58%. GuruFocus also compares Gerald W. Mclaughlin's trading performance to market benchmark return within the same time period. The performance of stocks bought by Gerald W. Mclaughlin within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Gerald W. Mclaughlin's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Gerald W. Mclaughlin

Average Return

Average return per transaction

Outperforming Transactions

0 out of 2 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	9.25
Relative Return to S&P 500(%)	15.41

Gerald W. Mclaughlin Ownership Network

Ownership Network List of Gerald W. Mclaughlin

No Data

Ownership Network Relation of Gerald W. Mclaughlin

Gerald W. Mclaughlin Owned Company Details

What does Neos Therapeutics Inc do?

Who are the key executives at Neos Therapeutics Inc?

Gerald W. Mclaughlin is the director & Chief Executive Officer of Neos Therapeutics Inc. Other key executives at Neos Therapeutics Inc include Chief Financial Officer Richard I Eisenstadt , SVP & General Counsel John M Limongelli , and Chief Commercial Officer Thomas P Mcdonnell .

Neos Therapeutics Inc (NEOS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Neos Therapeutics Inc (NEOS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Neos Therapeutics Inc (NEOS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Neos Therapeutics Inc (NEOS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Neos Therapeutics Inc Insider Transactions

No Available Data

What does Skye Bioscience Inc do?

Who are the key executives at Skye Bioscience Inc?

Gerald W. Mclaughlin is the director of Skye Bioscience Inc. Other key executives at Skye Bioscience Inc include 10 percent owner 5am Partners Vii, Llc , 10 percent owner John D Diekman , and 10 percent owner 5am Ventures Vii, L.p. .

Skye Bioscience Inc (SKYE) Insider Trades Summary

Over the past 18 months, Gerald W. Mclaughlin made no insider transaction in Skye Bioscience Inc (SKYE). Other recent insider transactions involving Skye Bioscience Inc (SKYE) include a net purchase of 5,656,074 shares made by 5am Partners Vii, Llc , and a net purchase of 1,762,000 shares made by Punit Dhillon .

In summary, during the past 3 months, insiders sold 0 shares of Skye Bioscience Inc (SKYE) in total and bought 450,000 shares, with a net purchase of 450,000 shares. During the past 18 months, 0 shares of Skye Bioscience Inc (SKYE) were sold and 5,663,122 shares were bought by its insiders, resulting in a net purchase of 5,663,122 shares.

Skye Bioscience Inc (SKYE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Skye Bioscience Inc Insider Transactions

No Available Data

What does Aytu BioPharma Inc do?

Who are the key executives at Aytu BioPharma Inc?

Gerald W. Mclaughlin is the director of Aytu BioPharma Inc. Other key executives at Aytu BioPharma Inc include Chief Financial Officer Mark K Oki , Chief Operating Officer Christopher Brooke , and Chief Business Officer Jarrett Disbrow .

Aytu BioPharma Inc (AYTU) Insider Trades Summary

Over the past 18 months, Gerald W. Mclaughlin made no insider transaction in Aytu BioPharma Inc (AYTU). Other recent insider transactions involving Aytu BioPharma Inc (AYTU) include a net purchase of 348,371 shares made by Joshua R. Disbrow , a net purchase of 100,000 shares made by Greg Pyszczymuka , and a net purchase of 90,000 shares made by Mark K Oki .

In summary, during the past 3 months, insiders sold 0 shares of Aytu BioPharma Inc (AYTU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aytu BioPharma Inc (AYTU) were sold and 40,219 shares were bought by its insiders, resulting in a net purchase of 40,219 shares.

Aytu BioPharma Inc (AYTU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aytu BioPharma Inc Insider Transactions

No Available Data

What does Allarity Therapeutics Inc do?

Who are the key executives at Allarity Therapeutics Inc?

Gerald W. Mclaughlin is the director of Allarity Therapeutics Inc. Other key executives at Allarity Therapeutics Inc include Chief Financial Officer Joan Yvonne Brown , director & Chief Executive Officer Steve Carchedi , and Chief Scientific Officer Steen Knudsen .

Allarity Therapeutics Inc (ALLR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Allarity Therapeutics Inc (ALLR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Allarity Therapeutics Inc (ALLR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Allarity Therapeutics Inc (ALLR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Allarity Therapeutics Inc Insider Transactions

No Available Data

Gerald W. Mclaughlin Mailing Address

Above is the net worth, insider trading, and ownership report for Gerald W. Mclaughlin. You might contact Gerald W. Mclaughlin via mailing address: 227 Washington Street, Suite 200, Conshohocken Pa 19428.

Discussions on Gerald W. Mclaughlin

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.